Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

NCT03229200 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

297

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Leukemia, B-cell
Graft Vs Host Disease
Solid Tumor

Interventions

DRUG: Ibrutinib

Sponsor

Pharmacyclics Switzerland GmbH

Collaborators

[object Object]